Montreux Equity Partners is a private investment firm dedicated to building the leading healthcare companies of tomorrow. Our portfolio companies meet the most compelling domestic and global healthcare needs. We currently have over $440 million under management.
Since 1993, we have invested in more than 50 companies across the healthcare industry. We focus on commercial stage companies that possess highly differentiated products and services. At the time of investment, a company will typically have $5 to $50 million in revenues. We typically invest $10-20 million per company, and our capital fuels product expansion, new market entry, and strategic acquisitions.
We have a cohesive team that works closely together across all aspects of the investment process, from diligence, to investment decisions, to portfolio management. Our team is complementary with unique operational, financial, and clinical expertise. We leverage this expertise through active support of our investments.
|Epirus Biopharmaceuticals||4/2014||Series B||$36M||5|
|GC Aesthetics||2/2014||Private Equity||$60M||3|
|Epirus Biopharmaceuticals||7/2012||Venture Round||$5M||2|
|Epirus Biopharmaceuticals||4/2012||Venture Round||$8.08M||2|
|Pivot Medical||11/2011||Series C||$32M||4|
|GC Aesthetics||10/2010||Venture Round||$30M||1|
|Tobira Therapeutics||9/2010||Series B||$31M||5|
|Avantis Medical Systems||6/2010||Debt||$2.81M||1|
|Transcept Pharmaceuticals||3/2007||Series D||$40M||8|
|Avantis Medical Systems||11/2006||Series B||$12M||2|